Publication details
Dapagliflozin a studie DECLARE – budoucnost léčby diabetes mellitus?
| Title in English | Dapagliflozin and the DECLARE study – the future of treating diabetes mellitus? |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | dapagliflozin; DECLARE; mortality |
| Description | SGLT2 – gliflozins are a possible new treatment of diabetes mellitus type 2. The mechanism of action is excretion of glucose by the kidneys. The fi rst mortality clinical trial with SGLT2 empagliflozin was finished in 2015 and other studies are currently running. Dapaglifl ozin has a large clinical trial programme, and meta-analysis data from smaller studies have shown a decrease in cardiovascular endpoints. This eff ect is probably a result of several mechanisms: reduction in blood sugar; blood pressure lowering; reduction in weight; and a diuretic effect. DECLARE is an international clinical trial of dapagliflozin, which is also running in the Czech Republic; the suspected trial closure is in 2018-19. The dapagliflozin clinical trial programme does not only include diabetes mellitus type 2 patients, but also type 1, as well as pediatric patients. |